Related Experiment Video

Updated: Nov 23, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.2K

Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer

Zhu Zeng1, Biao Yang2, Zhengyin Liao1

  • 1Department of Abdominal Oncology, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China.

Future Oncology (London, England)
|January 5, 2021
PubMed

Insights

Immunotherapy, particularly immune checkpoint inhibitors, offers survival benefits for gastric cancer (GC) patients. This review summarizes current GC immunotherapy trials, biomarkers, and limitations.

Area of Science:

  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Gastric cancer is a leading cause of cancer death globally.
  • Immunotherapy has emerged as a significant advancement in cancer treatment.
  • Immune checkpoint inhibitors (ICIs) target pathways like CTLA4 and PD-1/PD-L1.

Purpose of the Study:

  • To review current clinical trials of ICIs in gastric cancer.
  • To identify predictive biomarkers for ICI efficacy in GC.
  • To discuss the existing limitations of immunotherapy in gastric cancer treatment.

Main Methods:

  • Literature review of clinical trials and research studies.
  • Analysis of data on ICI efficacy and safety in gastric cancer.
  • Synthesis of information on predictive biomarkers and treatment challenges.

Main Results:

  • ICIs have demonstrated survival benefits in gastric cancer patients.
  • Several biomarkers are being investigated to predict response to ICIs.
  • Limitations include resistance mechanisms and potential toxicities.

Conclusions:

  • Immune checkpoint inhibitors represent a promising therapeutic strategy for gastric cancer.
  • Further research is needed to optimize ICI therapy and overcome current limitations.
  • Biomarker-driven approaches are crucial for personalized gastric cancer treatment.
Keywords:
CTLA4PD-1/PD-L1biomarkersgastric cancergastroesophageal junction cancerimmune checkpoint inhibitors

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.4K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

822

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
876
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K